The surgical robotics market has spent two decades perfecting mechanical arms that translate a surgeon's hand movements into precise incisions. Now, a Seoul-based startup emerging from one of South Korea's premier medical centers thinks the next battle won't be won with better hardware—it'll be won with better data.
Rosota, spun out of Seoul National University Hospital's Medical Spatial Computing Lab, closed a ₩1.5 billion seed round (roughly $965,000) this past July. FuturePlay led the financing, with checks from Schmidt and ZDVC. The 2026 vintage is small by global surgical robotics standards, where Series B rounds routinely clear nine figures. But for a team still operating out of a university lab, with staff somewhere in the single digits, it's a start.
What caught FuturePlay's attention wasn't another robotic arm. It was Rosota's pitch around systems designed from the ground up to ingest surgical video, motion data, and multimodal sensor feeds, then convert those streams into training datasets for machine-learning models. The company's vision, according to CEO Yechan Seo, centers on real-time support for surgeon judgment, not just remote control of instruments.
Whether that vision translates into a commercially viable product remains an open question. But the investor thesis is revealing.
Data Sovereignty and the Korean Market
FuturePlay, a Seoul-based deep-tech venture firm and studio, framed the deal around something that sounds almost geopolitical: data sovereignty. In public comments accompanying the funding announcement, the firm pointed to the surprisingly low penetration of incumbent surgical robots in South Korea and argued that accumulating high-quality domestic surgical data represented a strategic imperative. Rosota, in this telling, isn't just another medical device startup—it's a potential "sovereign" player in surgical AI.
That language may sound overwrought. But it reflects a broader tension in medical AI, where training data often flows to centers of capital and compute power, leaving smaller markets dependent on algorithms trained elsewhere. FuturePlay's bet is that Korea can—and should—build its own stack.
Schmidt, a seed-stage accelerator and TIPS operating partner linked to DSC Investment, joined the round, as did ZDVC, an early-stage Korean VC that backs companies across sectors. Neither disclosed their check sizes.
What's Actually Being Built
Rosota describes itself as building infrastructure, not just instruments. That's a subtle but important distinction in a field where most players still focus on mechanical precision and ergonomics. The startup's approach centers on the data layer: capturing surgical footage, instrument telemetry, and sensor readings, then structuring that information so machine-learning models can learn from it.
According to the company's website and press statements—language that remains somewhat high-level—the ambition is to create systems that can "understand surgical scenes in real time." What that means in practice isn't entirely clear yet. Does the AI flag anomalies? Suggest instrument angles? Predict complications? Rosota hasn't released clinical data or detailed use cases. For now, it's a research-stage play.
Seo, who holds a background from SNU College of Medicine and was co-first author on a 2024 paper in BMC Medical Informatics and Decision Making, leads the company alongside co-founders Minwoo Choi and Dongho Lee. All three have roots in SNU's medicine and mechanical engineering programs, and the team still operates out of SNUH's MediSC Lab, which sits within the Department of Convergence Medicine.
The startup has shown early technical progress—though again, at a research scale. In January, Rosota hosted R:rise, a symposium where nine research teams presented work on robotic systems and AI integration to SNUH faculty and industry guests. In March, it exhibited ALES—its Affordable Laparoscopic End-2-End Suturing Robot platform—at Automation World 2026 in Seoul. ALES is positioned as a research tool for what the company calls "physical AI," with high-frequency teleoperation and AI-ready infrastructure.
That's the kind of language that gets thrown around a lot in robotics circles these days. The proof will come when the system moves from lab benches to operating rooms.
What the Money Buys
The seed capital, Rosota says, will fund core R&D hiring, upgrades to surgical-data collection hardware, AI model development, and expansion of its clinical collaboration network. LinkedIn job postings from mid-2026 listed openings for robotics AI and 3D reconstruction researchers—roles that suggest the company is still building foundational technical capacity.
Seo's stated ambition is to create an environment where AI amplifies surgeon capability, allowing patients globally to access high-quality surgery. That's a big vision. The more immediate focus appears to be on surgical-data infrastructure rather than the mechanical arms themselves. In other words, Rosota is betting that the real moat in next-generation surgical robotics isn't in joints and actuators—it's in the data layer underneath.
The company maintains an active collaboration with SNUH's MediSC Lab, naturally. A cobot surgical-robot training system developed jointly with the hospital drew some media attention in March. Rosota currently lists between two and ten employees on LinkedIn, a number that's almost certainly set to climb as the startup converts funding into headcount.
The Competitive Landscape
Surgical robotics funding stayed relatively active through the first half of 2026, with capital flowing to both established players expanding their indications and startups exploring new modalities. Petal Surgical, for instance, raised funding in June for an incisionless histotripsy platform—a completely different approach to minimally invasive surgery.
The broader competitive field includes Intuitive's da Vinci 5, which still holds commanding market share, alongside Medtronic's Hugo, Johnson & Johnson's Ottava (which has faced delays), CMR Surgical's Versius, and a handful of others trying to chip away at Intuitive's dominance. Most of those systems remain focused on teleoperation: the surgeon controls the robot in real time.
Industry analyses from early 2026 note that AI in surgical robotics is still largely about augmenting surgeon information and planning, not replacing human judgment. No regulatory body is anywhere close to approving autonomous surgery. Rosota's positioning—emphasizing data pipelines and AI-native architecture from the outset—represents a bet that the infrastructure layer will become a differentiator as the field matures.
Whether that thesis holds depends on a lot of variables: regulatory pathways, clinical validation, competitive moats, and whether surgical data really does become the valuable asset FuturePlay thinks it will be. For now, Rosota is a very early-stage team with academic pedigree, a small seed round, and a big idea about how surgical robotics should be built.
The next test will be whether they can move from research symposiums to real operating rooms. And that's a much harder problem than securing a million dollars in venture capital.
